Singapore, June 30 -- US-based biotech company Anixa Biosciences has announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology.

This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the company's novel approach to breast cancer prevention and treatment in South Korea through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world.

With this issued patent, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements Anixa's existing patent p...